Skip to main content
Clinical Trials/EUCTR2014-001546-25-NL
EUCTR2014-001546-25-NL
Active, not recruiting
Phase 1

Short versus extended antibiotic treatment with a carbapenem for high-risk febrile neutropenia in hematology patients with Fever of Unknown Origin: a randomized multicenter open-label non-inferiority trial. - SHORT-trial

VU University Medical Center0 sites240 target enrollmentNovember 19, 2014
ConditionsFebrile neutropeniaMedDRA version: 19.1Level: PTClassification code 10063581Term: Stem cell transplantSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 19.1Level: LLTClassification code 10002969Term: Aplastic anemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 19.1Level: LLTClassification code 10003999Term: BacteremiaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 19.1Level: LLTClassification code 10007810Term: Catheter related infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 19.1Level: LLTClassification code 10028566Term: MyelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.1Level: LLTClassification code 10062957Term: Catheter bacteraemiaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 19.1Level: PTClassification code 10025310Term: LymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.1Level: LLTClassification code 10024329Term: LeukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.1Level: PTClassification code 10056520Term: Catheter site infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 19.1Level: PTClassification code 10016288Term: Febrile neutropeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Febrile neutropenia
Sponsor
VU University Medical Center
Enrollment
240
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 19, 2014
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
VU University Medical Center

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients with malignant hematological diseases being treated with cytotoxic chemotherapy or stem cell transplantation;
  • 2\.High\-risk neutropenia;
  • 4\.Age 18 years or older;
  • 5\.Written informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 220
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 20

Exclusion Criteria

  • 1\.Contraindications to use of imipenem\-cilastatin or meropenem such as allergy, previous severe side\-effects or previous microbiological cultures with carbapenem\-resistant microorganism(s).
  • 2\.Corticosteroid use \=10 mg per day prednisolone or equivalent for more than 3 consecutive days during the previous 7 days.
  • 3\.Clinically or microbiologically documented infection.
  • 4\.Symptoms of septic shock (systolic blood pressure \<90 mm Hg unresponsive to fluid resuscitation and/or oliguria (urine production \<500mL/day).
  • 5\.Previous enrollment in this study during the same episode of neutropenia.
  • 6\.Any critical illness for which Intensive Care Unit treatment is required.
  • 7\.Legal incompetency

Outcomes

Primary Outcomes

Not specified

Similar Trials